Effector Protein RNP Complexes for Precise HSC Gene Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying hematopoietic stem cells (HSCs) to treat genetic blood diseases like sickle cell anemia and β-thalassemia are limited in precision and efficacy, particularly in editing specific genes such as HBB, HBG1, and HBG2, which are associated with these disorders.
Innovation Solution
The use of engineered polypeptides and guide nucleic acids, specifically CRISPR/Cas systems, to form RNP complexes that bind to target sequences in HSCs, enabling precise nucleic acid editing by insertion, deletion, or substitution of nucleotides, thereby modifying genes like HBB, HBG1, and HBG2 to correct genetic mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If CRISPR/Cas systems are used to modify HSCs, then manufacturing precision of gene editing is improved, but device complexity increases
Solution Approach 1:
The patent segments the CRISPR system into separate functional components: guide RNA molecules that direct targeting and effector proteins that execute editing. This segmentation allows independent optimization of each component for precision while managing overall system complexity through modular assembly into RNP complexes.
Solution Approach 2:
The patent introduces RNP complexes as intermediary structures that mediate between the guide RNA and target DNA. These pre-formed complexes serve as controlled intermediaries that enhance editing precision by ensuring proper guide RNA-effector protein pairing before target engagement, while managing complexity through standardized complex formation protocols.
2Manufacturing precision
If RNP complexes are used for nucleic acid editing, then manufacturing precision is improved, but loss of time in complex formation increases
Solution Approach 1:
The patent applies preliminary action by pre-forming RNP complexes outside the cell before introducing them to HSCs. This advance preparation of precisely matched guide RNA-effector protein complexes ensures high editing precision upon delivery, while the actual complex formation occurs beforehand, separating the time-intensive assembly step from the cellular editing process.
3Reliability
If gene editing is performed on HSCs, then reliability of disease treatment is improved, but cell viability may deteriorate
Solution Approach 1:
The patent employs disposable RNP complexes that are introduced into HSCs, perform their editing function, and then degraded. These transient, non-integrating complexes deliver precise gene editing while minimizing long-term persistence in the cell, thereby reducing the risk of off-target effects and maintaining cell viability while ensuring reliable disease treatment.
Solution Approach 2:
The patent utilizes parameter changes by delivering effector proteins with controlled nuclease activity levels and using guide RNAs with optimized binding affinities. By carefully tuning these parameters, the system achieves sufficient editing reliability to correct disease-causing mutations while limiting excessive cellular damage that would compromise HSC viability and function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the retention of cell viability and multi-lineage development potential in HSCs, enabling effective treatment of genetic blood diseases by correcting disease-associated gene sequences, as demonstrated by indel formation and cell proliferation assays.
Implementation Method 1
the second region hybridizes to a target sequence of the target nucleic acid
Implementation Method 2
the polypeptide at least partially binds to the first region to form an RNP complex
Implementation Method 3
the RNP complex, upon hybridization of the second region to the target nucleic, modifies the target nucleic acid of the HSC
Implementation Method 4
compositions, systems, and methods may leverage nucleic acid modification activities, such as nucleic acid editing
Data Source
AI summary
Provided herein are compositions, systems, and methods for engineering hematopoietic stem cells that engineered by using polypeptides, such as effector proteins, and guide nucleic acids. Also, provided herein are the engineered hematopoietic stem cells, methods of manufacturing such hematopoietic stem cells, and methods of treating a disease or disorder using such hematopoietic stem cells.